Ilumya

(tildrakizumab)
1 ML tildrakizumab-asmn 100 MG/ML Prefilled Syringe [Ilumya]
NO BLACK BOX WARNING

Dosage & administration

Most viewed Ilumya resources

Billing and Coding

drug label

Ilumya prescribing information

Have more Ilumya questions?

Submit MSL Request
Learn More

Need to report an Ilumya issue?

ONLINE FORM
Report adverse event
Learn More

prior authorization

Ilumya Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRAND
Coverage Authorization Request
Coverage Authorization Appeals
Learn More

Benefits investigation

Ilumya Support Enrollment Form
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Ilumya Financial assistance options

Co-pay savings program

commercial only
Ilumya Support Enrollment Form
Enroll in Patient Savings Program
Learn More

Bridge program

commercial only
Ilumya Support Enrollment Form
Ilumya Early Access Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Ilumya Support Enrollment Form
Learn More

patient education

Ilumya Patient education

Getting started on Ilumya

NOT PROVIDED BY BRAND
Instructions For Use: Plaque Psoriasis

Patient toolkit

About Ilumya
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Ilumya
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Before & After
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure - Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Ilumya FAQs

What is the risk of ILUMYA use during pregnancy?Limited available data on the use of ILUMYA during pregnancy are insufficient to inform a drug-associated risk of adverse developmental outcomes. Human IgG is known to cross the placental barrier; therefore, ILUMYA may be transferred from the mother to the fetus. An embryofetal developmental study conducted with tildrakizumab in pregnant monkeys revealed no treatment-related effects to the developing fetus when tildrakizumab was administered subcutaneously during organogenesis to near parturition at doses up to 159 times the maximum recommended human dose (MRHD). When dosing was continued until parturition, a small increase in neonatal death was observed at 59 times the MRHD.
What is the background risk of birth defects and miscarriage during pregnancy?All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
What does the animal data on ILUMYA use during pregnancy show?In an embryofetal developmental study, subcutaneous doses up to 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during organogenesis to gestation day 118. No maternal or embryofetal toxicities were observed at doses up to 300 mg/kg. Tildrakizumab crossed the placenta in monkeys. In a pre- and postnatal developmental study, subcutaneous doses up to 100 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks from gestation day 50 to parturition. Neonatal deaths occurred in the offspring of one control monkey, two monkeys at 10 mg/kg dose, and four monkeys at 100 mg/kg dose. The clinical significance of these nonclinical findings is unknown.
What is the risk of ILUMYA use during lactation?There are no data on the presence of tildrakizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. Tildrakizumab was detected in the milk of monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ILUMYA and any potential adverse effects on the breastfed child from ILUMYA or from the underlying maternal condition.
What is the safety and effectiveness of ILUMYA in pediatric patients?ILUMYA has not been established as safe and effective in pediatric patients under the age of 18.
What is the geriatric use of ILUMYA?During Phase 2 and 3 trials, 92 subjects aged 65 or older and 17 subjects aged 75 or older were exposed to ILUMYA 100mg. Although there were no observed differences in safety or efficacy between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects.
FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.